Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Abbisko Cayman Ltd
2256Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The company's product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services. Abbisko Cayman Limited has co-discovery collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of novel molecules; and BeiGene, Ltd. on the combination therapy of fexagratinib and tislelizumab, an anti-PD-1 antibody for treating urothelial cancer with FGFR2/3 genetic alterations. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China. Address: Building 3, Shanghai, China
Analytics
Objectif de Cours de WallStreet
88.58 HKDRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés 2256
Analyse des dividendes 2256
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes 2256
Valorisation des titres 2256
financières 2256
Résultats | 2019 | Dynamique |